drugset
drugset / Trial / NCT05317741

SAD Study of IA-14069

NCT05317741 ↗

Phase 1 Completed 40 enrolled ILAb Co., Ltd.
RandomizedSequentialTriple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, food effect, and pharmacodynamics following a single oral dose of IA-14069 in healthy male subjects.

Timeline

Start
2021-08-23
Primary completion
2022-09-08
Completion
2022-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject IA-14069 Unknown — Oral

Indications

No indication recorded.